Biodesix’s Earnings Call Contradictions: Test Launch Delays and Sales Rep Productivity Targets Don’t Align

Date of Call: Feb 26, 2026

Financials Results

• Revenue: Q4: $28.8M, up 41% YOY; FY: $88.5M, up 24% YOY
• Gross Margin: Q4: 83%, up 400 bps YOY; FY: 81%, up 300 bps YOY

Guidance:

• Revenue for 2026 expected to be $106M to $112M, representing 23% annual growth at the midpoint over 2025.
• Expect continued improvement towards sustained adjusted EBITDA positivity.

Business Commentary:

Revenue and Financial Performance:

• Biodesix reported revenue of $28.8 million for Q4 and $88.5 million for fiscal 2025, representing an increase of 41% and 24% over the respective prior year periods.
• The growth was driven by lung diagnostics, where revenue increased by 46% and 22% for Q4 and fiscal 2025, respectively.

Lung Diagnostics and Test Volumes:

• The company's lung diagnostics test volumes were 18,000 and 62,600 for Q4 and fiscal 2025, showing a growth of 23% and 15%.
• This increase was attributed to the expanded sales strategy, which included primary care and pulmonology, leading to improved triaging and management of lung nodules.

Operational and Margin Improvements:

• Biodesix achieved a gross margin percentage of 83% for Q4 and 81% for fiscal 2025, marking a 400 basis point and 300 basis point improvement, respectively.
• Improvements were driven by growth in lung diagnostic testing, advancements in reimbursement, and optimization of testing workflows.

Development Services and Partnerships:

• Development services revenue grew by 12% and 41% for Q4 and fiscal 2025, resulting from both existing contracts and new agreements.
• The company announced partnerships with Thermo Fisher Scientific and Bio-Rad Laboratories, highlighting its capabilities in delivering high-quality diagnostic tests.

Adjusted EBITDA and Cash Position:

• Biodesix reported adjusted EBITDA positivity of $530,000 for Q4, marking an improvement of 113% over the previous year.
• The company's cash position was strengthened by additional proceeds from an at-the-market offering, providing flexibility and supporting operational improvements.

Sentiment Analysis:

Overall Tone: Positive

• Achieved first ever positive adjusted EBITDA quarter, strong revenue growth of 41% in Q4, gross margins of 83%, and delivered 23% growth in test volumes. Management stated: 'We finished 2025 strong with excellent fourth quarter performance... We are operating from a position of increasing strength and remain confident in our ability to execute.'

Q&A:

• Question from Kyle Mikson (Canaccord Genuity): Trying to understand how much of a step down we should expect with the revenue and volume in Q1 relative to Q4, considering potential flush/prior period pull-forward, deductible dynamics, and weather.
  Response: Step down is expected to be consistent with historic seasonality, with a typical Q1 ASP decline and volume step down; weather disruptions and ~$1M in Q4 collections from claims over 1 year are factors.

• Question from Kyle Mikson (Canaccord Genuity): Could you elaborate on new tests in the pipeline and what you aim to launch in the next 12-18 months, and what excites you most about the future portfolio?
  Response: No commercial launches planned within the next 12 months; the pipeline includes advancements in MRD, immunotherapy selection, and prostate cancer tests. Most exciting is showcasing the development team's capabilities.

• Question from Kyle Mikson (Canaccord Genuity): What is the approximate volume accounted for by the primary care rep base, and how do you feel about that mix looking to 2026?
  Response: Primary care volume grew to 12% of total Nodify orders in Q4; both primary care and pulmonology sales teams are performing well and expected to continue growing, with ~24 reps to be added in 2026.

• Question from William Ruby (TD Cowen): Do you feel well positioned from a cash perspective, and is there any need to add additional cushion in 2026?
  Response: Cash position is strong; the balance sheet is strengthened, providing flexibility going forward.

• Question from William Ruby (TD Cowen): What are the most likely upside levers to 2026 guidance?
  Response: Upside levers include increased sales rep productivity as the team gains tenure, continued ASP stability/growth, and excitement about the development services portfolio.

• Question from William Ruby (TD Cowen): Have you seen any additional evidence of stage shift by referring through primary care, and would you do real-world studies to demonstrate this?
  Response: Physicians have shared positive data on stage shift, and the company encourages independent publication; a formal study may be pursued, but the focus is on increasing awareness.

• Question from Andrew Brackmann (William Blair): Any new updates on CLARIFY data readouts and potential for ALTITUDE study readout?
  Response: CLARIFY: submitting interim analysis and subgroups for publication without waiting for CHEST. ALTITUDE: enrollment stopped; earliest data readout will be in 2027, missing the 2026 CHEST timeline.

• Question from Andrew Brackmann (William Blair): Are the primary care and pulmonology sales efforts complementary or cannibalistic?
  Response: They are complementary; the strategy starts with building relationships in pulmonology to triage high-risk patients, while primary care helps manage the broader referral network, reducing clinic burden.

• Question from Thomas Flaten (Lake Street Capital Markets): What is the allocation of new sales force additions in 2026 between PCP and pulmonology?
  Response: Not disclosed; hiring will be agile and need-based, guided by current performance, with the majority expected to be a blend of associate and primary care-focused reps.

• Question from Thomas Flaten (Lake Street Capital Markets): How do you see differential growth rates through 2026 between primary care and pulmonology channels?
  Response: Growth is seen as an opportunity in both channels; reimbursement is consistent, and the focus is on reaching more Medicare-age patients.

• Question from Thomas Flaten (Lake Street Capital Markets): Any insight on HEDIS guidelines?
  Response: No material updates; both parties continue to prioritize and will provide updates in 2026.

• Question from John Wilkin (Craig-Hallum): Are you able to parse out how much of the test growth came from new reps versus existing sales force in 2025?
  Response: Growth was balanced, with the majority from existing reps as most new reps were hired later; new reps are expected to contribute more in 2026.

• Question from John Wilkin (Craig-Hallum): How productive were reps hired earlier in 2025 by year-end, and how long does it take for new reps to ramp?
  Response: New reps typically pay for themselves in about 3 months, but ramping continues beyond that; growth trajectory is strong with opportunity for all reps.

Contradiction Point 1

Productivity Targets for Sales Reps

Contradiction on the minimum productivity target per sales rep.

Thomas Flaten (Lake Street Capital Markets) - Thomas Flaten (Lake Street Capital Markets)

20260227-2025 Q4: The allocation is not yet disclosed and will be based on current performance. The hiring will be agile and need-based. - [Scott Hutton](CFO)

How will new sales hires be allocated in 2026 between primary care and pulmonology? - Alexander Vukasin (Canaccord Genuity Corp.)

20251104-2025 Q3: The ramp-up has been consistent, with plans to build back to a minimum of $1 million per sales rep in productivity. - [Scott Hutton](CFO)

Contradiction Point 2

Guidance for New Test Development

Contradiction on the timeline for launching new commercial tests.

Kyle Mikson (Canaccord Genuity) - Kyle Mikson (Canaccord Genuity)

20260227-2025 Q4: No new tests are planned for commercial launch within the next 12 months. - [Scott Hutton](CFO)

Can you elaborate on the new tests in the pipeline beyond what was shared on the call, your launch plans for the next 12–18 months, and what you’re most excited about for the future portfolio? - Margarate Boeye (William Blair & Company L.L.C.)

20251104-2025 Q3: Exciting updates will be shared at the upcoming AMP Annual Meeting R&D Day... The company plans to change the perception of its underappreciated pipeline. - [Scott Hutton](CFO)

Contradiction Point 3

Sales Force Expansion Strategy and Productivity Expectations

Contradiction on the expected productivity timeline for new sales reps.

John Wilkin (Craig-Hallum) - John Wilkin (Craig-Hallum)

20260227-2025 Q4: The company is pleased with the caliber of new reps. Historically, it takes about 3 months for a new rep to become profitable, and this trend has continued. - [Robin Cowie](CFO)

What is the productivity of reps hired in 2025 by year-end, and what is their average ramp-up time? - William Ruby (TD Cowen, for Dan)

2025Q2: Confidence is high because the pilot demonstrated they can ramp similarly to pulmonology reps and pay for themselves in a comparable timeframe. Early hires are on a similar trajectory. - [Scott Hutton](CRO)

Contradiction Point 4

Primary Care Rep Contribution and Ramp-up

Contradiction on the immediate contribution of new primary care reps versus the gradual ramp-up timeline.

John Wilkin (Craig-Hallum) - John Wilkin (Craig-Hallum)

20260227-2025 Q4: Growth was balanced, but the majority came from existing reps since most new reps were hired later in the year. - [Robin Cowie](CFO)

How much of the ~8,000 test growth in 2025 came from new versus existing reps? - Andrew Brackmann (William Blair)

2025Q2: Confidence is increasing due to reaffirming experiences from the pilot. The first class of primary care sales reps has started in the field, and ordering from primary care has increased from 4% to 9% of Nodify tests. - [Scott Hutton](CRO)

Contradiction Point 5

Sales Rep Hiring and Allocation Strategy

Contradiction on whether hiring is primarily for primary care or a blended approach.

Thomas Flaten (Lake Street Capital Markets) - Thomas Flaten (Lake Street Capital Markets)

20260227-2025 Q4: The majority of new hires will be a blend of associate sales professionals and primary care-focused professionals. - [Scott Hutton](CEO)

Okay, let's see. The user wants me to rewrite the input into one concise earnings-call question. The input is: "What will be the allocation of new sales force hires in 2026 between primary care and pulmonology?" First, I need to check the rules. The output must be exactly one line, only the final question text, end with a question mark if possible. No explanations or anything else. If the input isn't a question, is too vague, or lacks info, output as-is.The input is a question. It's asking about the allocation of new sales hires in 2026 between two specific areas. The original question seems clear, but maybe it can be made more concise. Let me see. "Allocation" could be phrased as "distribution" perhaps. "Between primary care and pulmonology" is specific. The year is 2026. Is there a way to shorten it without losing meaning? Maybe "How will new sales force hires in 2026 be allocated between primary care and pulmonology?" That's a bit shorter. Alternatively, "What is the 2026 sales force hire allocation between primary care and pulmonology?" That's also concise. But the original uses "allocation of new sales force hires in 2026 between..." Maybe "allocation" is okay. Let me check if the original is already concise enough. The original is 13 words. The rewritten version could be shorter. Let's try: "How will new sales force hires in 2026 be allocated between primary care and pulmonology?" That's 14 words. Hmm, maybe not shorter. Alternatively, "What is the allocation of new 2026 sales hires between primary care and pulmonology?" That's 11 words. Wait, "new sales force hires" could be "new sales hires" to shorten. Also, "allocation" is a noun, so "What is the allocation..." versus "How will... be allocated..." Both are valid. The user wants it concise. The original uses "allocation of new sales force hires in 2026 between..." Maybe changing "sales force hires" to "sales hires" and reordering the time. So, "What is the allocation of new 2026 sales hires between primary care and pulmonology?" That's a bit shorter. But is "sales hires" clear enough? The original says "sales force hires," which is more precise. Maybe "sales force hires" is better. Alternatively, "How will new sales force hires in 2026 be allocated between primary care and pulmonology?" That's 14 words. The original is 13. Maybe the original is already concise enough. But the user wants it rewritten into one concise question. Alternatively, "What portion of 2026 new sales hires will go to primary care versus pulmonology?" That's shorter. "Portion" instead of "allocation." "Go to" instead of "allocation between." But does that capture the same meaning? Maybe. But the user might prefer to keep the exact terms. The original uses "allocation," which is a bit formal. Maybe "distribution" is another synonym. But the key is to make it a single concise question. The original is already a clear question. If I can make it more concise without losing clarity, that's better. Let me try again: "How will new 2026 sales hires be allocated between primary care and pulmonology?" That's 12 words. "New sales hires" instead of "new sales force hires." Is "sales hires" clear enough? In the context of an earnings call, "sales hires" might be understood as new hires in the sales force. So that's acceptable. So the final question would be: "How will new 2026 sales hires be allocated between primary care and pulmonology?" Ends with a question mark. Alternatively, "What is the 2026 sales hire allocation between primary care and pulmonology?" That's 11 words. But maybe the user wants to keep "allocation of new sales force hires." Let me check the original again. The original is: "What will be the allocation of new sales force hires in 2026 between primary care and pulmonology?" If we remove "in 2026" and place it after, maybe: "What will be the 2026 allocation of new sales force hires between primary care and pulmonology?" That's 13 words. But the original has "in 2026." Maybe rephrasing to "for 2026" is better. "What will be the allocation of new sales force hires for 2026 between primary care and pulmonology - Sung Ji Nam (Scotiabank)

2025Q1: The majority of new hires are for the primary care segment. - [Scott Hutton](CEO)